ABBV Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -0.15% compared to AbbVie's net margin of 23.56%. AbbVie's return on equity of 61.64% beat Gilead Sciences's return on equity of 2.5%.

AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.11%. On the other hand Gilead Sciences has an analysts' consensus of $110.51 which suggests that it could grow by 4.38%. Given that Gilead Sciences has higher upside potential than AbbVie, analysts believe Gilead Sciences is more attractive than AbbVie.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Gilead Sciences offers a yield of 2.93% to investors and pays a quarterly dividend of $0.79 per share. AbbVie pays 257.71% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $15.1B, which are larger than Gilead Sciences quarterly revenues of $7.6B. AbbVie's net income of -$22M is lower than Gilead Sciences's net income of $1.8B. Notably, AbbVie's price-to-earnings ratio is 88.32x while Gilead Sciences's PE ratio is 286.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 4.63x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -0.15% compared to AbbVie's net margin of 15.24%. AbbVie's return on equity of 61.64% beat Johnson & Johnson's return on equity of 19.98%.

AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.11%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.71%. Given that Johnson & Johnson has higher upside potential than AbbVie, analysts believe Johnson & Johnson is more attractive than AbbVie.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Johnson & Johnson offers a yield of 3.04% to investors and pays a quarterly dividend of $1.24 per share. AbbVie pays 257.71% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AbbVie's net income of -$22M is lower than Johnson & Johnson's net income of $3.4B. Notably, AbbVie's price-to-earnings ratio is 88.32x while Johnson & Johnson's PE ratio is 28.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 4.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -0.15% compared to AbbVie's net margin of 32.59%. AbbVie's return on equity of 61.64% beat Eli Lilly and's return on equity of 80.24%.

AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.11%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 19.93%. Given that Eli Lilly and has higher upside potential than AbbVie, analysts believe Eli Lilly and is more attractive than AbbVie.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Eli Lilly and offers a yield of 0.64% to investors and pays a quarterly dividend of $1.50 per share. AbbVie pays 257.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are larger than Eli Lilly and quarterly revenues of $13.5B. AbbVie's net income of -$22M is lower than Eli Lilly and's net income of $4.4B. Notably, AbbVie's price-to-earnings ratio is 88.32x while Eli Lilly and's PE ratio is 71.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 16.91x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -0.15% compared to AbbVie's net margin of 31.35%. AbbVie's return on equity of 61.64% beat Vertex Pharmaceuticals's return on equity of -3.23%.

AbbVie has a consensus price target of $211.73, signalling downside risk potential of -0.11%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -3.07%. Given that Vertex Pharmaceuticals has more downside risk than AbbVie, analysts believe AbbVie is more attractive than Vertex Pharmaceuticals.

AbbVie has a beta of 0.614, which suggesting that the stock is 38.616% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 2.97%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie pays 257.71% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

AbbVie quarterly revenues are $15.1B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. AbbVie's net income of -$22M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, AbbVie's price-to-earnings ratio is 88.32x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 6.67x versus 12.06x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.